Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...
Moderna Inc. Plans USD 1 Billion Investment in Shanghai for mRNA Vaccine Production
US-based mRNA specialist Moderna Inc. (NASDAQ: MRNA) has revealed further details of its entry into...
CSPC Pharmaceutical Group Receives Marketing Approval for Desvenlafaxine in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving marketing approval in China for...
AbbVie’s Rinvoq Receives NMPA Approval for Moderate to Severe Crohn’s Disease Treatment
US pharmaceutical firm AbbVie (NYSE: ABBV) has announced receiving market approval from the National Medical...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
CDE Releases 72nd Batch of Generic Reference Preparations with New Specifications
The Center for Drug Evaluation (CDE) has released the 72nd batch of chemical generic reference...
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...
Abbisko Therapeutics’ EGFR Inhibitor ABSK112 Clears FDA for Global Phase I NSCLC Study
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Jacobio Pharma’s KRAS Inhibitor Glecirasib Advances to Pivotal Pancreatic Cancer Trial
China-based Jacobio Pharma (HKG: 1167) has announced that it has received the green light from...
InnoCare Pharma Initiates Clinical Trial for TYK2 Inhibitor ICP-488 in Psoriasis Patients
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced a significant milestone in the clinical...
ZAP-X Gyroscopic Radiosurgery Platform Receives NMPA Approval for Brain Tumor Treatment
US-based Zap Surgical Systems Inc. has announced that it has received market approval in China...
NMPA Approves Pitolisant for Narcolepsy-Related Excessive Daytime Drowsiness and Cataplexy
The National Medical Products Administration (NMPA) has approved pitolisant as a treatment for excessive daytime...
Ascentage Pharma’s Olverembatinib Gets NMPA Greenlight for Phase III Study in Ph+ ALL
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the National...
Amoytop Biotech’s Pegfilgrastim (Y Shape) Approved for Marketing by NMPA
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has received marketing approval from the National Medical...
Jacobio Pharma Retakes Global Rights to SHP2 Inhibitors After Terminating AbbVie Agreement
China-based Jacobio Pharma (HKG: 1167) has announced the cancellation of a licensing agreement with US...
Helio Genomics’ Sister Company LAMH Wins NMPA Approval for Liver Cancer Test in China
Helio Genomics has announced that its ‘sister company’ Laboratory for Advanced Medicine & Health Group...
NHSA Unveils Updated National Reimbursement Drug List Rules for 2023
The National Healthcare Security Administration (NHSA) has released the updated rules that will govern this...
Binhui Biopharmaceutical and Topgene Biotechnology Partner for New Drug R&D and AI Platform Development
Wuhan-based Binhui Biopharmaceutical and Hubei Topgene Biotechnology Co., Ltd have announced a strategic partnership to...
Huadong Medicine’s Mirvetuximab Soravtansine Heads for Priority Review by China’s CDE
The China’s Center for Drug Evaluation (CDE) website has indicated that Huadong Medicine Co., Ltd...
NMPA Proposes Revisions to “Drug Inspection Management Measures”, Seeks Public Feedback
The National Medical Products Administration (NMPA) has released revised provisions of the “Drug Inspection Management...